Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Adalimumab in Crohn's Disease
NCT00195715Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2004
- Primary completion
- Mar 2006
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by Abbott Laboratories. Primary endpoint: Percentage of Subjects Achieving Clinical Remission at 156 weeks. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00195715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195715.